These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 36100306)

  • 1. Estimating deaths averted and cost per life saved by scaling up mRNA COVID-19 vaccination in low-income and lower-middle-income countries in the COVID-19 Omicron variant era: a modelling study.
    Savinkina A; Bilinski A; Fitzpatrick M; Paltiel AD; Rizvi Z; Salomon J; Thornhill T; Gonsalves G
    BMJ Open; 2022 Sep; 12(9):e061752. PubMed ID: 36100306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 vaccination in Sindh Province, Pakistan: A modelling study of health impact and cost-effectiveness.
    Pearson CAB; Bozzani F; Procter SR; Davies NG; Huda M; Jensen HT; Keogh-Brown M; Khalid M; Sweeney S; Torres-Rueda S; ; ; Eggo RM; Vassall A; Jit M
    PLoS Med; 2021 Oct; 18(10):e1003815. PubMed ID: 34606520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimated global public health and economic impact of COVID-19 vaccines in the pre-omicron era using real-world empirical data.
    Yang J; Vaghela S; Yarnoff B; De Boisvilliers S; Di Fusco M; Wiemken TL; Kyaw MH; McLaughlin JM; Nguyen JL
    Expert Rev Vaccines; 2023; 22(1):54-65. PubMed ID: 36527724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of Coronavirus Disease 2019 Vaccination in Low- and Middle-Income Countries.
    Siedner MJ; Alba C; Fitzmaurice KP; Gilbert RF; Scott JA; Shebl FM; Ciaranello A; Reddy KP; Freedberg KA
    J Infect Dis; 2022 Nov; 226(11):1887-1896. PubMed ID: 35696544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing the impacts of COVID-19 vaccination programme's timing and speed on health benefits, cost-effectiveness, and relative affordability in 27 African countries.
    Liu Y; Procter SR; Pearson CAB; Montero AM; Torres-Rueda S; Asfaw E; Uzochukwu B; Drake T; Bergren E; Eggo RM; Ruiz F; Ndembi N; Nonvignon J; Jit M; Vassall A
    BMC Med; 2023 Mar; 21(1):85. PubMed ID: 36882868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential population-level effectiveness of one-dose HPV vaccination in low-income and middle-income countries: a mathematical modelling analysis.
    Bénard É; Drolet M; Laprise JF; Gingras G; Jit M; Boily MC; Bloem P; Brisson M
    Lancet Public Health; 2023 Oct; 8(10):e788-e799. PubMed ID: 37777288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis.
    COVID-19 Cumulative Infection Collaborators
    Lancet; 2022 Jun; 399(10344):2351-2380. PubMed ID: 35405084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling the potential economic benefits of an oral SARS-CoV-2 vaccine during an outbreak of COVID-19.
    Patenaude B; Ballreich J
    BMC Public Health; 2022 Sep; 22(1):1792. PubMed ID: 36131266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Economic Impact of Smoking and of Reducing Smoking Prevalence: Review of Evidence.
    Ekpu VU; Brown AK
    Tob Use Insights; 2015; 8():1-35. PubMed ID: 26242225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study.
    Watson OJ; Barnsley G; Toor J; Hogan AB; Winskill P; Ghani AC
    Lancet Infect Dis; 2022 Sep; 22(9):1293-1302. PubMed ID: 35753318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Public health impact and economic value of booster vaccination with Pfizer-BioNTech COVID-19 vaccine, bivalent (Original and Omicron BA.4/BA.5) in the United States.
    Di Fusco M; Marczell K; Thoburn E; Wiemken TL; Yang J; Yarnoff B
    J Med Econ; 2023; 26(1):509-524. PubMed ID: 36942976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries.
    Canfell K; Kim JJ; Brisson M; Keane A; Simms KT; Caruana M; Burger EA; Martin D; Nguyen DTN; Bénard É; Sy S; Regan C; Drolet M; Gingras G; Laprise JF; Torode J; Smith MA; Fidarova E; Trapani D; Bray F; Ilbawi A; Broutet N; Hutubessy R
    Lancet; 2020 Feb; 395(10224):591-603. PubMed ID: 32007142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19 Vaccination and Estimated Public Health Impact in California.
    Tan ST; Park HJ; Rodríguez-Barraquer I; Rutherford GW; Bibbins-Domingo K; Schechter R; Lo NC
    JAMA Netw Open; 2022 Apr; 5(4):e228526. PubMed ID: 35452106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation.
    Sandmann FG; Davies NG; Vassall A; Edmunds WJ; Jit M;
    Lancet Infect Dis; 2021 Jul; 21(7):962-974. PubMed ID: 33743846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The global health and economic value of COVID-19 vaccination.
    Sevilla JP; Burnes D; Knee JS; Di Fusco M; Kyaw MH; Yang J; Nguyen JL; Bloom DE
    BMJ Glob Health; 2024 Sep; 9(9):. PubMed ID: 39244220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis.
    Drolet M; Laprise JF; Martin D; Jit M; Bénard É; Gingras G; Boily MC; Alary M; Baussano I; Hutubessy R; Brisson M
    Lancet Infect Dis; 2021 Nov; 21(11):1598-1610. PubMed ID: 34245682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimating the health impact of vaccination against ten pathogens in 98 low-income and middle-income countries from 2000 to 2030: a modelling study.
    Li X; Mukandavire C; Cucunubá ZM; Echeverria Londono S; Abbas K; Clapham HE; Jit M; Johnson HL; Papadopoulos T; Vynnycky E; Brisson M; Carter ED; Clark A; de Villiers MJ; Eilertson K; Ferrari MJ; Gamkrelidze I; Gaythorpe KAM; Grassly NC; Hallett TB; Hinsley W; Jackson ML; Jean K; Karachaliou A; Klepac P; Lessler J; Li X; Moore SM; Nayagam S; Nguyen DM; Razavi H; Razavi-Shearer D; Resch S; Sanderson C; Sweet S; Sy S; Tam Y; Tanvir H; Tran QM; Trotter CL; Truelove S; van Zandvoort K; Verguet S; Walker N; Winter A; Woodruff K; Ferguson NM; Garske T;
    Lancet; 2021 Jan; 397(10272):398-408. PubMed ID: 33516338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimating the health effects of COVID-19-related immunisation disruptions in 112 countries during 2020-30: a modelling study.
    Hartner AM; Li X; Echeverria-Londono S; Roth J; Abbas K; Auzenbergs M; de Villiers MJ; Ferrari MJ; Fraser K; Fu H; Hallett T; Hinsley W; Jit M; Karachaliou A; Moore SM; Nayagam S; Papadopoulos T; Perkins TA; Portnoy A; Minh QT; Vynnycky E; Winter AK; Burrows H; Chen C; Clapham HE; Deshpande A; Hauryski S; Huber J; Jean K; Kim C; Kim JH; Koh J; Lopman BA; Pitzer VE; Tam Y; Lambach P; Sim SY; Woodruff K; Ferguson NM; Trotter CL; Gaythorpe KAM
    Lancet Glob Health; 2024 Apr; 12(4):e563-e571. PubMed ID: 38485425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar.
    Abu-Raddad LJ; Chemaitelly H; Ayoub HH; AlMukdad S; Yassine HM; Al-Khatib HA; Smatti MK; Tang P; Hasan MR; Coyle P; Al-Kanaani Z; Al-Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul-Rahim HF; Nasrallah GK; Al-Kuwari MG; Butt AA; Al-Romaihi HE; Al-Thani MH; Al-Khal A; Bertollini R
    N Engl J Med; 2022 May; 386(19):1804-1816. PubMed ID: 35263534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial.
    Oda Y; Kumagai Y; Kanai M; Iwama Y; Okura I; Minamida T; Yagi Y; Kurosawa T; Greener B; Zhang Y; Walson JL
    Lancet Infect Dis; 2024 Apr; 24(4):351-360. PubMed ID: 38141632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.